Recent data support the feasibility of concomitant administration of SZCs to initiate/up-titrate heart failure-specific medical therapies including renin-angiotensin system inhibitors (RASIs) and mineralocorticoid receptor antagonists (MRAs), which commonly cause hyperkalemia and thus can be limited in their implementation [2]. This evidence concerns the gene NR3C2 and heart failure.